Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics (Premium)
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

JCL Bioassay revises full-year consolidated outlook for FY 2014


Thursday, 1 May 2014 03:00am EDT 

JCL Bioassay Corp:Full-year consolidated outlook for revenue of 2,207 mln yen lowered from 2,376 mln yen, for fiscal year ended March 31, 2014.Full-year operating profit outlook of 84 mln yen raised from 20 mln yen.Full-year ordinary profit outlook of 172 mln yen raised from 30 mln yen.Full-year net profit (loss) outlook of 62 mln yen raised from (51 mln) yen.Full-year earnings (loss) per share outlook of 18.08 yen raised from (14.83) yen.Revenue outlook lowered due to decreased revenue from domestic bio analysis business and postponed trial of subsidiary, and profit outlook raised due to expense reduction, depreciation of yen and extraordinary profit on endowment insurance contract cancellation. 

Company Quote

455.0
15.0 +3.41%
1:59am EDT